57 Views | 23 Downloads
Christine Fennema-Notestine, PhD, University of California, San Diego (UCSD), 9500 Gilman Dr., #0738, La Jolla, CA 92093-0738, Phone: 858-246-0605; Fax: 858-246-0556. Email: fennema@ucsd.edu
This work was supported in part by awards from National Institutes of Health (R01 MH05621, T. Hulgan and A. Kallianpur; K24 MH097673, S.L. Letendre; the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) N01 MH2205 and HHSN271201000036C, to I. Grant; R01 MH107345, R.K. Heaton and S.L. Letendre; and P30 MH62512, R. Heaton). The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Government. We gratefully acknowledge all individuals who participated in CHARTER studies, as well as all CHARTER study investigators
The authors report no biomedical financial interests or potential conflicts of interest relevant to this manuscript beyond those participating through the NIH funding stated above:
Christine Fennema-Notestine, PhD1,2 has no disclosures to report, other than participating through NIH funding stated above. Tricia A. Thornton-Wells, PhD3 has no disclosures to report, other than participating through NIH funding stated above. Todd Hulgan, PhD4 has no disclosures to report, other than the NIH funding stated above. Scott Letendre, MD5 has no disclosures to report, other than the NIH funding stated above. Ronald J. Ellis, MD, PhD6 has no disclosures to report, other than participating through NIH funding stated above. Donald R. Franklin, Jr., BS1 has no disclosures to report, other than participating through NIH funding stated above. Albert M. Anderson, MD7 has no disclosures to report. Robert K. Heaton, PhD1 has no disclosures to report, other than the NIH funding stated above. Cinnamon S. Bloss, PhD1,8 has no disclosures to report. I. Grant, MD1 has no disclosures to report, other than the NIH funding stated above. Asha R. Kallianpur, MD, MPH9,10 has no disclosures to report, other than the NIH funding stated above.